SPS
DNLI icon

Susquehanna Portfolio Strategies’s Denali Therapeutics DNLI Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.44M Buy
211,474
+53,578
+34% +$1.1M 0.09% 263
2026
Q1 		$3.03M Sell
157,896
-9,817
-6% -$195K 0.05% 401
2025
Q4 		$2.77M Buy
+167,713
New +$2.83M 0.04% 436

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna Portfolio Strategies's DNLI Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Denali Therapeutics (DNLI) stake by 34% in Q2 2026, buying an estimated $1.1M and bringing the position to 211,474 shares worth $5.44M. The position accounts for 0.09% of the portfolio, ranked #263.

Susquehanna Portfolio Strategies first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Susquehanna Portfolio Strategies held 211,474 shares of Denali Therapeutics worth $5.44M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 53,578 Denali Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Denali Therapeutics made up 0.09% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #263 holding.
  • Susquehanna Portfolio Strategies first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.